Organon has agreed to sell the JADA System to Laborie Medical Technologies for up to $465 million, aimed at reducing debt and enhancing future investments in women's health biopharma.

Target Information

Organon (NYSE: OGN) is a global healthcare company dedicated to delivering impactful medicines and solutions aimed at improving everyday health. Recently, the company announced its agreement with Laborie Medical Technologies Corp. to acquire the JADA System, a medical device designed to manage and treat abnormal postpartum uterine bleeding or hemorrhage. This transaction is valued at up to $465 million, which includes $440 million payable at closing and an additional contingent payment of up to $25 million based on specific revenue targets for 2026. The agreement will also result in approximately 100 employees transferring to Laborie.

Industry Overview

The demand for innovative healthcare technologies, particularly in women’s health, is experiencing significant growth. Laborie Medical Technologies has established itself as a leader in medical diagnostics and therapeutics, focusing on maternal health. With advanced technologies such as the JADA System, Laborie is well-positioned to meet the increasing need for effective postpartum management solutions. The global maternal health market is expanding, fueled by technological advances and increasing awareness about postpartum complications.

In recent years, maternal health initiatives have garnered more attention both from healthcare providers and policymakers. The urgency to address postpartum hemorrhage (PPH), which remains a leading cause of maternal mortality, underscores th